Enlivex Therapeutics
Enlivex Therapeutics
ENLV
NASDAQ
1.12
USD
2.75%
About
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state.
Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 39.4K |
| Three Month Average Volume | 1.1M |
| High Low | |
| Fifty-Two Week High | 4.59 USD |
| Fifty-Two Week Low | 1.15 USD |
| Fifty-Two Week High Date | 03 Apr 2024 |
| Fifty-Two Week Low Date | 05 Aug 2024 |
| Price and Volume | |
| Current Price | 1.3 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -8.17% |
| Thirteen Week Relative Price Change | -10.69% |
| Twenty-Six Week Relative Price Change | -63.17% |
| Fifty-Two Week Relative Price Change | -56.59% |
| Year-to-Date Relative Price Change | -59.34% |
| Price Change | |
| One Day Price Change | 4.42% |
| Thirteen Week Price Change | -4.41% |
| Twenty-Six Week Price Change | -59.50% |
| Five Day Price Change | 5.69% |
| Fifty-Two Week Price Change | -45.61% |
| Year-to-Date Price Change | -51.85% |
| Month-to-Date Price Change | -2.99% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.61754 USD |
| Book Value Per Share (Most Recent Quarter) | 1.42735 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.61754 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.42735 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.15445 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.56494 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.39618 USD |
| Normalized (Last Fiscal Year) | -1.33646 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.56494 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.39618 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.56494 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.39618 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.46893 USD |
| Cash Per Share (Most Recent Quarter) | 1.24582 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.51999 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.35159 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.20073 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -10.17% |
| Tangible Book Value (5 Year) | 25.39% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 43.29% |
| EPS Change (Trailing Twelve Months) | 14.39% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -23,436,000 |
| Net Debt (Last Fiscal Year) | -27,320,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 8 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,759,000 |
| Free Cash Flow (Trailing Twelve Months) | -22,366,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -55.65% |
| Return on Assets (Trailing Twelve Months) | -57.08% |
| Return on Assets (5 Year) | -39.16% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -66.88% |
| Return on Equity (Trailing Twelve Months) | -67.14% |
| Return on Equity (5 Year) | -46.09% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -63.33% |
| Return on Investment (Trailing Twelve Months) | -63.38% |
| Return on Investment (5 Year) | -43.65% |